Adicet Bio Files 8-K Report
Ticker: ACET · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1720580
| Field | Detail |
|---|---|
| Company | Adicet Bio, Inc. (ACET) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
TL;DR
Adicet Bio filed an 8-K, likely containing important updates for investors.
AI Summary
On October 16, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Adicet Bio is providing updates to the SEC, which could contain material information for investors regarding the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative events.
Key Numbers
- 001-38359 — Commission File Number (Identifies the company's SEC filing history.)
- 81-3305277 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Adicet Bio, Inc. (company) — Registrant
- October 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Boston, Massachusetts (location) — Principal Executive Offices
- resTORbio, Inc. (company) — Former Company Name
FAQ
What specific 'Other Events' are being disclosed by Adicet Bio, Inc. in this 8-K filing?
The provided excerpt does not detail the specific 'Other Events' being disclosed; it only lists the item as part of the filing's content.
What is the significance of the 'Regulation FD Disclosure' mentioned in the filing?
A Regulation FD Disclosure indicates that Adicet Bio, Inc. is providing information to the public that could be considered material, ensuring fair disclosure to all investors.
What was Adicet Bio, Inc.'s former name, and when did the name change occur?
Adicet Bio, Inc.'s former name was resTORbio, Inc., and the date of the name change was October 24, 2017.
Where are Adicet Bio, Inc.'s principal executive offices located?
Adicet Bio, Inc.'s principal executive offices are located at 131 Dartmouth Street, Floor 3, Boston, Massachusetts, 02116.
What is the filing date and the earliest event date reported in this 8-K?
The filing date and the date of the earliest event reported are both October 16, 2024.
Filing Stats: 665 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-10-16 07:01:05
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma
Filing Documents
- acet-20241016.htm (8-K) — 42KB
- acet-ex99_1.htm (EX-99.1) — 25KB
- img94724212_0.jpg (GRAPHIC) — 3KB
- 0000950170-24-114839.txt ( ) — 189KB
- acet-20241016.xsd (EX-101.SCH) — 24KB
- acet-20241016_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 16, 2024, Adicet Bio, Inc. (the "Company") issued a press release titled "Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome," a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On October 16, 2024, the Company announced that the U.S. Food and Drug Administration cleared the Company's Investigational New Drug amendment to evaluate ADI-001 in idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS). The Company plans to initiate enrollment for IIM and SPS patients as part of the ongoing Phase 1 trial in autoimmune diseases in the first quarter of 2025. The ADI-001 Phase 1 program in autoimmune diseases will have four separate arms, enrolling lupus nephritis and systemic lupus erythematosus patients into one arm, systemic sclerosis patients into a second arm, anti-neutrophil cytoplasmic autoantibody-associated vasculitis patients into a third arm, and IIM and SPS patients into a fourth arm. The fourth cohort combines several rare autoimmune muscle diseases into a single dose-finding population, including SPS and the following IIM subtypes: dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, polymyositis, and overlap myositis.
01 Exhibits
Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Adicet Bio, Inc. on October 16, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ADICET BIO, INC. Date: October 16, 2024 By: /s/ Nick Harvey Name: Title: Nick Harvey Chief Financial Officer